Antiangiogenic Agents in Cancer Therapy

This volume represents a compendium of scientific findings and approaches to the study of angiogenesis in cancer. The second edition of Antiangiogenic Agents in Cancer Therapy is intended to give a current perspective on the state-of-the-art of angiogenensis and therapy directed at this process. Antiangiogenesis is a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge.

Preface	p. v
Contributors	p. xi
List of Color Plates	p. xv
Basic Biology of Angiogenesis
Vascular Endothelial Growth Factor Family and Its Receptors	p. 3
The Cycle Between Angiogenesis, Perfusion, and Hypoxia in Tumors	p. 27
The Role of Integrins in Tumor Angiogenesis	p. 49
Tumor Endothelial Cell Abnormalities	p. 73
The Extracellular Matrix and VEGF Processing	p. 85
Endothelial Precursor Cells	p. 99
Role of Pericytes in Angiogenesis	p. 117
Newer Vascular Targets	p. 133
Chemokines in Angiogensis	p. 155
Angiopoietin/Tie2 Signaling Regulates Tumor Angiogenesis	p. 171
Imaging Angiogenesis	p. 189
Tumor Blood Vessels: Structure, Function, and Classification	p. 205
Lymphatic System in the Pathology of Cancer	p. 225
Translational Research in Tumor Angiogenesis
VEGF in the Adult: Implications for Anti-VEGF Therapies	p. 245
Normalization of Tumor Vasculature and Microenvironment: A Potential Mechanism of Action of Antiangiogenic Therapies	p. 261
Metronomic Low-Dose Antiangiogenic Chemotherapy in Mice and Man	p. 277
Small-Molecule Vascular Disrupting Agents in Cancer Therapy	p. 297
Normalization of Tumor Vasculature and Improvement of Radiation Response by Antiangiogenic Agents	p. 311
Challenges in Translating Antiangiogenic Therapy from the Bench to Bedside	p. 323
Regulation of Angiogenesis in Cancer and Its Therapeutic Implications	p. 331
Antiangiogenic Therapy in the Clinical Trial Results and Future Directions
Angiogenesis and Angiogenesis Inhibition in Sarcomas	p. 353
Antiangiogenesis Agents in Colorectal Cancer	p. 371
Antiangiogenic Therapy for Primary CNS Tumors	p. 385
Angiogenesis Inhibitors for the Treatment of Lung Cancer	p. 409
Antiangiogenic Therapy of Renal Cell Carcinoma	p. 427
Antiangiogenesis Therapies in Gynecologic Malignancies	p. 441
Antiangiogenic Agents in Myeloid Malignancies	p. 457
Angiogenesis in Malignant and Non-Malignant Pediatric Tumors	p. 475
Prognostic and Predictive Significance of Surrogate Biomarkers of Angiogenesis	p. 487
Endpoints for the Determination of Efficacy of Antiangiogenic Agents in Clinical Trials	p. 509
The Role of Imaging in the Clinical Development of Antiangiogenic Agents	p. 525
Index	p. 537
Table of Contents provided by Ingram. All Rights Reserved.

What is included with this book?

The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.

The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.

FREE SHIPPING

Amazon no longer offers textbook rentals. We do!

Antiangiogenic Agents in Cancer Therapy

Summary

Table of Contents

Supplemental Materials